ARTICLE | Product Development
Clawing towards approval
After 20 years, 2 companies and 1 rejection, FDA approves Marqibo for leukemia
August 20, 2012 7:00 AM UTC
After 20 years in development at two companies, Marqibo vincristine sulfate received accelerated approval from FDAthis month after Talon Therapeutics Inc. applied the lessons from a previous rejection by conducting a more thoroughly adjudicated study in a new cancer setting. Talon plans to launch the drug for late-stage acute lymphoblastic leukemia in 1Q13.
Marqibo is a nanoparticle-encapsulated formulation of vincristine designed to allow for dose intensification of the vinca alkaloid to facilitate activity against relapsed or refractory cancer without exacerbating toxicities...